ASCVD-话题@MedSci

#ASCVD#

32篇内容 | 3685人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2236682, encodeId=c03622366828b, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a> <a href='/topic/show?id=4b3610e57406' target=_blank style='color:#2F92EE;'>#Lp（a）#</a>, objectTitle=LDL-C降得再低，也不能抵消Lp(a)升高的心血管风险！Circulation杂志Meta分析, objectType=article, longId=850895, objectId=aeec850895f0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241113/1731469946803_8538692.png, objectUrl=/article/show_article.do?id=aeec850895f0, replyNumber=0, likeNumber=29, createdTime=2024-11-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=aeec850895f0, moduleTitle=LDL-C降得再低，也不能抵消Lp(a)升高的心血管风险！Circulation杂志Meta分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeec850895f0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2230909, encodeId=4bb122309090d, content=<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a> <a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=JACC-BTS 华科大同济医院汪道文/丁虎团队揭示超级增强子来源ABCA1-seRNA表观调控胆固醇稳态抗动脉粥样硬化新机制, objectType=article, longId=846621, objectId=6bed846621ea, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202401014/1728901627095_8538692.jpg, objectUrl=/article/show_article.do?id=6bed846621ea, replyNumber=0, likeNumber=106, createdTime=2024-10-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6bed846621ea, moduleTitle=JACC-BTS 华科大同济医院汪道文/丁虎团队揭示超级增强子来源ABCA1-seRNA表观调控胆固醇稳态抗动脉粥样硬化新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bed846621ea)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2224280, encodeId=5cb12224280fe, content=<a href='/topic/show?id=658d634305b' target=_blank style='color:#2F92EE;'>#残余胆固醇#</a> <a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a> <a href='/topic/show?id=fcf311e4286f' target=_blank style='color:#2F92EE;'>#ESC 2024#</a>, objectTitle=ESC 2024 | 专访黄榕翀教授：从年龄角度看残余胆固醇对ASCVD风险的新见解, objectType=article, longId=842019, objectId=fab2842019b7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240905/1725527450603_92910.png, objectUrl=/article/show_article.do?id=fab2842019b7, replyNumber=0, likeNumber=75, createdTime=2024-09-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=fab2842019b7, moduleTitle=ESC 2024 | 专访黄榕翀教授：从年龄角度看残余胆固醇对ASCVD风险的新见解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fab2842019b7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2216847, encodeId=e53f221684e65, content=<a href='/topic/show?id=07f25183043' target=_blank style='color:#2F92EE;'>#心血管疾病#</a> <a href='/topic/show?id=593c10e5975' target=_blank style='color:#2F92EE;'>#LDL-C#</a> <a href='/topic/show?id=53cc899384b' target=_blank style='color:#2F92EE;'>#血脂管理#</a> <a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=胡盛寿院士团队研究：达到这个LDL-C最佳水平，或可将死亡风险降至最低！, objectType=article, longId=835256, objectId=e969835256b7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240711/1720671030282_5579292.png, objectUrl=/article/show_article.do?id=e969835256b7, replyNumber=0, likeNumber=223, createdTime=2024-07-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e969835256b7, moduleTitle=胡盛寿院士团队研究：达到这个LDL-C最佳水平，或可将死亡风险降至最低！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e969835256b7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2197471, encodeId=04de219e4718f, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a> <a href='/topic/show?id=271d1131e6d7' target=_blank style='color:#2F92EE;'>#降低低密度脂蛋白胆固醇#</a> <a href='/topic/show?id=07ab1131e760' target=_blank style='color:#2F92EE;'>#inclisiran-first#</a>, objectTitle=打一针管半年！新型降脂药，可将“坏胆固醇”水平降低60% | ACC 2024, objectType=article, longId=819402, objectId=bda1819402bd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/patient-meeting-a-doctor-PAYSRMZ.jpg, objectUrl=/article/show_article.do?id=bda1819402bd, replyNumber=0, likeNumber=69, createdTime=2024-04-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=bda1819402bd, moduleTitle=打一针管半年！新型降脂药，可将“坏胆固醇”水平降低60% | ACC 2024, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bda1819402bd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2196834, encodeId=9fbb219683454, content=<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a> <a href='/topic/show?id=de4119403c2' target=_blank style='color:#2F92EE;'>#一级预防#</a> <a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=阿司匹林天天用，这10个问题一定要知道！, objectType=article, longId=818395, objectId=b1688183954b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668024406447_4754896.jpeg, objectUrl=/article/show_article.do?id=b1688183954b, replyNumber=0, likeNumber=278, createdTime=2024-04-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=b1688183954b, moduleTitle=阿司匹林天天用，这10个问题一定要知道！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1688183954b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2196337, encodeId=cc29219633e29, content=<a href='/topic/show?id=53cc899384b' target=_blank style='color:#2F92EE;'>#血脂管理#</a> <a href='/topic/show?id=a557333025c' target=_blank style='color:#2F92EE;'>#动脉粥样硬化性心血管疾病#</a> <a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=CGP指南|中国血脂管理指南（基层版2024年）, objectType=article, longId=817387, objectId=977581e387b4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-examining-medical-report-PJUYHWX.jpg, objectUrl=/article/show_article.do?id=977581e387b4, replyNumber=0, likeNumber=112, createdTime=2024-03-31, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=977581e387b4, moduleTitle=CGP指南|中国血脂管理指南（基层版2024年）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=977581e387b4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1271134, encodeId=840b12e113405, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=Lancet：他汀+依折麦布联合治疗vs高强度他汀单药治疗在ASCVD中的疗效更佳！, objectType=article, longId=734082, objectId=2b97e3408225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b97e3408225, replyNumber=0, likeNumber=125, createdTime=2022-08-02, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b97e3408225, moduleTitle=Lancet：他汀+依折麦布联合治疗vs高强度他汀单药治疗在ASCVD中的疗效更佳！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b97e3408225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271133, encodeId=33bc12e1133dc, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=PLoS One：不同降糖药物对2型糖尿病患者动脉粥样硬化性心血管疾病（ASCVD）风险评分的影响 , objectType=article, longId=733948, objectId=a522e33948a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a522e33948a6, replyNumber=0, likeNumber=100, createdTime=2022-07-31, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a522e33948a6, moduleTitle=PLoS One：不同降糖药物对2型糖尿病患者动脉粥样硬化性心血管疾病（ASCVD）风险评分的影响 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a522e33948a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271131, encodeId=4a4812e113106, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=《国家医保药品目录》落地：优化ASCVD患者的降脂方案，阿利西尤单抗直接医保应用, objectType=article, longId=293291, objectId=3ea9293291f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ea9293291f9, replyNumber=0, likeNumber=105, createdTime=2022-01-04, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ea9293291f9, moduleTitle=《国家医保药品目录》落地：优化ASCVD患者的降脂方案，阿利西尤单抗直接医保应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ea9293291f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271130, encodeId=036312e113075, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=Circulation：无冠状动脉钙化人群发生ASCVD事件的风险因素研究, objectType=article, longId=265043, objectId=3f83265043bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f83265043bf, replyNumber=0, likeNumber=131, createdTime=2021-12-14, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f83265043bf, moduleTitle=Circulation：无冠状动脉钙化人群发生ASCVD事件的风险因素研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f83265043bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271129, encodeId=2c0f12e11299b, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=GW-ICC 2021：超高危ASCVD人群如何降血脂？我国新版规范3条核心要点必读！, objectType=article, longId=219490, objectId=82542194906e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82542194906e, replyNumber=0, likeNumber=136, createdTime=2021-10-31, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82542194906e, moduleTitle=GW-ICC 2021：超高危ASCVD人群如何降血脂？我国新版规范3条核心要点必读！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82542194906e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271128, encodeId=fa5812e112840, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=JACC：高敏C反应蛋白可显著改变脂蛋白a相关ASCVD的风险, objectType=article, longId=217555, objectId=51ad21e55578, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51ad21e55578, replyNumber=0, likeNumber=133, createdTime=2021-09-25, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51ad21e55578, moduleTitle=JACC：高敏C反应蛋白可显著改变脂蛋白a相关ASCVD的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51ad21e55578)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271132, encodeId=3e2e12e113206, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=ESC 2021丨FOURIER全新结果：依洛尤单抗显著降低ASCVD患者所有血管床急性动脉事件的风险, objectType=article, longId=216528, objectId=e73f216528e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e73f216528e7, replyNumber=0, likeNumber=124, createdTime=2021-09-02, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e73f216528e7, moduleTitle=ESC 2021丨FOURIER全新结果：依洛尤单抗显著降低ASCVD患者所有血管床急性动脉事件的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e73f216528e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271127, encodeId=c31012e112732, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=JACC发布高甘油三酯血症患者降低ASCVD风险的临床指南, objectType=article, longId=215019, objectId=7d0e21501983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d0e21501983, replyNumber=0, likeNumber=130, createdTime=2021-07-31, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d0e21501983, moduleTitle=JACC发布高甘油三酯血症患者降低ASCVD风险的临床指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d0e21501983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271126, encodeId=bac612e1126c2, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=赵冬：ASCVD一级预防，LDL-C目标值和安全性再探讨, objectType=article, longId=205507, objectId=1abc20550ed2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1abc20550ed2, replyNumber=0, likeNumber=148, createdTime=2021-01-10, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1abc20550ed2, moduleTitle=赵冬：ASCVD一级预防，LDL-C目标值和安全性再探讨, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1abc20550ed2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271125, encodeId=f7f612e112556, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=OCC 2020丨颠覆性试验结果！鱼油用于ASCVD防治是时候了吗？, objectType=article, longId=195120, objectId=7e7b1951202f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e7b1951202f, replyNumber=0, likeNumber=120, createdTime=2020-06-03, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e7b1951202f, moduleTitle=OCC 2020丨颠覆性试验结果！鱼油用于ASCVD防治是时候了吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e7b1951202f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271124, encodeId=207512e11241d, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=OCC 2020丨彭道泉：强化降脂在超高危ASCVD患者中聚焦斑块逆转价值和新趋势, objectType=article, longId=195003, objectId=760919500377, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=760919500377, replyNumber=0, likeNumber=110, createdTime=2020-06-01, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=760919500377, moduleTitle=OCC 2020丨彭道泉：强化降脂在超高危ASCVD患者中聚焦斑块逆转价值和新趋势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=760919500377)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271123, encodeId=442c12e112352, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=Circulation：药费对ASCVD患者治疗不依从性的影响, objectType=article, longId=185082, objectId=d6f7185082d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6f7185082d1, replyNumber=0, likeNumber=123, createdTime=2019-12-24, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6f7185082d1, moduleTitle=Circulation：药费对ASCVD患者治疗不依从性的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6f7185082d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271122, encodeId=9a2312e1122ec, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=JACC：新胆固醇指南助力高危ASCVD患者的强化降脂治疗, objectType=article, longId=183084, objectId=57b71830841b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57b71830841b, replyNumber=0, likeNumber=125, createdTime=2019-11-18, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57b71830841b, moduleTitle=JACC：新胆固醇指南助力高危ASCVD患者的强化降脂治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57b71830841b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASCVD

2020-05-29

梅斯管理员

#ASCVD# #Lp（a）#

LDL-C降得再低，也不能抵消Lp(a)升高的心血管风险！Circulation杂志Meta分析

2024-11-13发表于上海

梅斯管理员

#动脉粥样硬化# #ASCVD#

JACC-BTS 华科大同济医院汪道文/丁虎团队揭示超级增强子来源ABCA1-seRNA表观调控胆固醇稳态抗动脉粥样硬化新机制

2024-10-14发表于上海

梅斯管理员

#残余胆固醇# #ASCVD# #ESC 2024#

ESC 2024 | 专访黄榕翀教授：从年龄角度看残余胆固醇对ASCVD风险的新见解

2024-09-05发表于上海

梅斯管理员

#心血管疾病# #LDL-C# #血脂管理# #ASCVD#

胡盛寿院士团队研究：达到这个LDL-C最佳水平，或可将死亡风险降至最低！

2024-07-25发表于上海

梅斯管理员

#ASCVD# #降低低密度脂蛋白胆固醇# #inclisiran-first#

打一针管半年！新型降脂药，可将“坏胆固醇”水平降低60% | ACC 2024

2024-04-08发表于陕西省

梅斯管理员

#阿司匹林# #一级预防# #ASCVD#

阿司匹林天天用，这10个问题一定要知道！

2024-04-03发表于陕西省

梅斯管理员

#血脂管理# #动脉粥样硬化性心血管疾病# #ASCVD#

CGP指南|中国血脂管理指南（基层版2024年）

2024-03-31发表于陕西省

doctorzheng

#ASCVD#

Lancet：他汀+依折麦布联合治疗vs高强度他汀单药治疗在ASCVD中的疗效更佳！

2022-08-02

doctorzheng

#ASCVD#

PLoS One：不同降糖药物对2型糖尿病患者动脉粥样硬化性心血管疾病（ASCVD）风险评分的影响

2022-07-31

doctorzheng

#ASCVD#

《国家医保药品目录》落地：优化ASCVD患者的降脂方案，阿利西尤单抗直接医保应用

2022-01-04

doctorzheng

#ASCVD#

Circulation：无冠状动脉钙化人群发生ASCVD事件的风险因素研究

2021-12-14

doctorzheng

#ASCVD#

GW-ICC 2021：超高危ASCVD人群如何降血脂？我国新版规范3条核心要点必读！

2021-10-31

doctorzheng

#ASCVD#

JACC：高敏C反应蛋白可显著改变脂蛋白a相关ASCVD的风险

2021-09-25

doctorzheng

#ASCVD#

ESC 2021丨FOURIER全新结果：依洛尤单抗显著降低ASCVD患者所有血管床急性动脉事件的风险

2021-09-02

doctorzheng

#ASCVD#

JACC发布高甘油三酯血症患者降低ASCVD风险的临床指南

2021-07-31

doctorzheng

#ASCVD#

赵冬：ASCVD一级预防，LDL-C目标值和安全性再探讨

2021-01-10

doctorzheng

#ASCVD#

OCC 2020丨颠覆性试验结果！鱼油用于ASCVD防治是时候了吗？

2020-06-03

doctorzheng

#ASCVD#

OCC 2020丨彭道泉：强化降脂在超高危ASCVD患者中聚焦斑块逆转价值和新趋势

2020-06-01

doctorzheng

#ASCVD#

Circulation：药费对ASCVD患者治疗不依从性的影响

2019-12-24

doctorzheng

#ASCVD#

JACC：新胆固醇指南助力高危ASCVD患者的强化降脂治疗

2019-11-18